Quilter Plc decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 77,358 shares of the company’s stock after selling 3,474 shares during the quarter. Quilter Plc’s holdings in Johnson & Johnson were worth $12,637,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Morton Brown Family Wealth LLC grew its position in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after acquiring an additional 78 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $39,000. Cardinal Capital Management Inc. increased its stake in shares of Johnson & Johnson by 333.3% in the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the period. First Bank & Trust raised its holdings in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after buying an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $84,000. Institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Trading Down 0.3 %
Shares of JNJ opened at $168.31 on Tuesday. The business’s 50-day moving average price is $176.07 and its 200 day moving average price is $171.13. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.
Johnson & Johnson Dividend Announcement
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock valued at $40,960,735 over the last quarter. Company insiders own 0.35% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have issued reports on JNJ. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Sanford C. Bernstein reduced their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Citigroup raised their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Atlantic Securities decreased their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Finally, Credit Suisse Group began coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price on the stock. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.